Peptides Semax Selank Nad+Cagrilintide Epithalon factory direct sale RT15
TDS 12 Inquiries
45234-02-4
Pharmaceutical Grade
99%
Hong Kong
customizable
10vials/box
2027-04-02
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceWhite powder
Solid
Lys-Glu is a dipeptide formed from L-lysine and L-glutamic acid residues. It has a role as a metabolite.Certificates-
TDS
Basic Info-
Product Name:
Lysylglutamic acid
Other Name:L-Glutamic acid,L-lysyl-;L-Glutamic acid,N-L-lysyl-;Glutamic acid,N-L-lysyl-;L-Lysyl-L-glutamic acid;Lysylglutamic acid;Vilon;Vilon (peptide);1072: PN: EP2071334 SEQID: 1140 claimed protein;1072: PN: WO2009077864 SEQID: 1140 claimed protein;72: PN: EP2161028 PAGE: 10 claimed protein;911649-46-2
CAS No.:45234-02-4
Molecular Formula:C11H21N3O5
InChIKeys:InChIKey=UGTZHPSKYRIGRJ-YUMQZZPRSA-N
Molecular Weight:275.3
Exact Mass:275.30
UNII:H34V7IM5ML
DSSTox ID:DTXSID50196442
HScode:2924199090
Categories:
Characteristics-
PSA:
156
XLogP3:0.66840
Density:1.29 g/cm3
Melting Point:195-197 °C
Boiling Point:596.4ºC at 760 mmHg
Flash Point:314.5ºC
Storage Conditions:-15°C
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Location:
Building 1, Floor 2, No. 96 Banhe Road, Huangpu District, Guangzhou City, Room 2164
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
12
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA
"> -
-
Inquiry History12 Inquiries
Country Product Purchase Quantity Date Posted
United Arab Emirates
Vesugen Peptide 98% Powder 45234-02-4 Senwayer
1 G Nov 14, 2023
Philippines
VILON
300 G Aug 26, 2026
United States
Cartalax
20 MG Aug 6, 2026
United States
Vilon
1 KG Jul 8, 2026
Brazil
Cartalax
5 MT Apr 17, 2026
Poland
Peptides
10 MT Aug 24, 2026
United States
Cartalax
20 MG Aug 17, 2026
Australia
Cartalax
200 MG Jul 3, 2026
United States
Cartalyx
1 PCS Mar 12, 2026
United States
Cartalax
1 G Jul 25, 2026
Netherlands
Cartalax
1 G Apr 26, 2026
United States
Vesugen 10mg
20 PCS Mar 3, 2026 Post an enquiry for this product
